InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,634.80
(
0.80%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.81
(
-0.12%
)
Bitcoin
60,155.96
(
-0.01%
)
Post# of 252477
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

puravida

Send PM Follow Ignore
Followers 36
Posts 1736
Boards Moderated 0
Alias Born 05/13/2011

puravida

Re: None

Thursday, 06/27/2019 8:30:13 AM

Thursday, June 27, 2019 8:30:13 AM

Post# of 252477
DOVA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR DOPTELET® (AVATROMBOPAG) FOR TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)

Company Strengthens Thrombocytopenia Portfolio with ITP Approval and Expanded Partnership with Salix for Chronic Liver Disease (CLD) Indication

Company to Host Conference Call at 9am EST



http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-announces-fda-approval-supplemental-new
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up